Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections

Bin Liu(VenatoRx Pharmaceuticals (United States)), Robert E. Lee Trout(VenatoRx Pharmaceuticals (United States)), Guo‐Hua Chu(VenatoRx Pharmaceuticals (United States)), Daniel McGarry(VenatoRx Pharmaceuticals (United States)), Randy W. Jackson(VenatoRx Pharmaceuticals (United States)), Jodie C. Hamrick(VenatoRx Pharmaceuticals (United States)), Denis M. Daigle(VenatoRx Pharmaceuticals (United States)), Susan M. Cusick(VenatoRx Pharmaceuticals (United States)), Cecilia Pozzi(University of Siena), Filomena De Luca(University of Siena), Manuela Benvenuti(University of Siena), Stefano Mangani(University of Siena), Jean‐Denis Docquier(University of Siena), Jason Weiss(University of North Texas), Daniel C. Pevear(VenatoRx Pharmaceuticals (United States)), L Xerri(VenatoRx Pharmaceuticals (United States)), Christopher J. Burns(VenatoRx Pharmaceuticals (United States))
Journal of Medicinal Chemistry
November 25, 2019
10.1021/acs.jmedchem.9b01518
Cited by 297Open Access
Full Text

Abstract

and carbapenem-resistant Enterobacteriaceae. Taniborbactam is the first pan-spectrum β-lactamase inhibitor to enter clinical development.

Related Papers

No related papers found

Powered by citation graph analysis